Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07456033) titled 'A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma' on March 2.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: GlaxoSmithKline
Condition:
Asthma
Intervention:
Drug: Depemokimab
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: March 6, 2026
Target Sample Size: 456
To know more, visit https://clinicaltrials.gov/study/NCT07456...